Advertisement

Oxaliplatin: Update on a Active and Safe Dach Platinum Complex

  • P. Soulié
  • E. Raymond
  • J. L. Misset
  • E. Cvitkovic

Abstract

Since the introduction of cisplatin (CDDP) in oncological chemotherapy, numerous attempts have been made to synthetize derivates that would increase the therapeutic index of this cytotoxic class, while expanding its indications. During the past decade, many platinum based therapeutic programs have been aimed at circumventing cisplatin/carboplatin resistance, as primary or acquired treatment failure represents the major limitation of the two platinum complexes currently available in the clinic [1, 2].

Keywords

Ovarian Cancer Germ Cell Tumor Advanced Colorectal Cancer Platinum Complex Cross Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Burchenal JH, Kalaher K, Dew K et al: Rationale for the development of platinum analogs. Cancer Treat Rep 63:1493–1498 (1979).PubMedGoogle Scholar
  2. [2]
    Christian MC: The current status of new platinum analogs. Semin Oncol 19:720–733 (1992).PubMedGoogle Scholar
  3. [3]
    Burchenal JH, Lokys L, Turkevich J, et al: 1,2-Diaminocyclohexane platinum derivatives of potential clinical vlaue. Recent Results Cancer Res 74:146–155 (1980).CrossRefPubMedGoogle Scholar
  4. [4]
    Tashiro R, Kawada Y, Sakuri Y et al: Antitumor activity of a new platinum complex, oxalato (trans-I-1,2-diaminocyclohexane) platinum (II): New experimental data. Biomed Pharmacother 43:251 (1989).CrossRefPubMedGoogle Scholar
  5. [5]
    Mathé G, Kidani Y, Sekiguchi M et al: Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed & Pharmacother 43:237–250 (1989).CrossRefGoogle Scholar
  6. [6]
    Inagaki K, Kidani Y: Differences in binding of (1,2-cyclohexane) platinum (II) isomers with d(GpG). Inorg Chem. 25:1–3 (1986).CrossRefGoogle Scholar
  7. [7]
    Kidani Y: Oxaliplatin. Drugs Future 14(6):529–532 (1989).Google Scholar
  8. [8]
    Boudny V, Vrana O, Gaucheron F et al: Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum (II) complexes. Nucleic Acids Res. 20(2):267–272(1992).CrossRefPubMedGoogle Scholar
  9. [9]
    Kohn KW: Molecular mechanisms of cross-linking by alkylating agents and platinum complexes, in: Molecular actions and targets for cancer chemotherapeutic agents, Sartorelli AC, Lazo JS, Bertino JR, eds., Academic press, New York (1981).Google Scholar
  10. [10]
    Micetich KC, Barnes D, Erickson LC: A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylaton)-platinum (II) and cis-diamminedichloroplatinum (II) on L1210 cells. Cancer Res. 45:4043–4047(1985).PubMedGoogle Scholar
  11. [11]
    Jennerwein MM, Eastman A, Khokhar A: Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum (II) complexes. Chem Bil. Interact. 70:39–49 (1989).CrossRefGoogle Scholar
  12. [12]
    Myers TG, Pauli KD, Fojo AT et al: Multivariate analysis of high-flux screening data using the DISCOVER computer program package: integrated analysis of activity patterns and molecular structure features of platinum complexes. Proc Am As Can Res 35:371 (1994).Google Scholar
  13. [13]
    Pendyala L, Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Research 53: 5970–5976 (1993).PubMedGoogle Scholar
  14. [14]
    Alvarez M, Ortuzar W, Rixe O et al: Cross resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues. Proc Am As Can Res 35:439 (1994).Google Scholar
  15. [15]
    Mathé G, Chenu E, Bourut C et al: Experimental study of three platinum complexes: CDDP, CBDCA and l-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes. Proc Am As Can Res 30:872 (1989).Google Scholar
  16. [16]
    Ortuzar W, Pauli K, Rixe O et al: Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistant sublines. Proc Am As Can Res 35:332 (1994).Google Scholar
  17. [17]
    Massari C, Brienza S, Rotarski M: Oxaliplatin, Transplatin® comparative pharmacokinetics in normal and impaired renal function patients. Proc. Am As Can Res 35:242 (1994).Google Scholar
  18. [18]
    Misset JL, Kidani Y, Gastiaburu J et al: Oxalatoplatinum (l-OHP): Experimental and clinical studies. in: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Howell SB ed., Plenum Press, New york (1991).Google Scholar
  19. [19]
    Extra JM, Espie M, Calvo F et al: Phase I study of Oxaliplatin in patients with advanced Cancer. Cancer Chemoter Pharmacol 25:299–303 (1990).CrossRefGoogle Scholar
  20. [20]
    Caussanel JP, Lévi F, Brienza S et al: Phase I trial of 5-day continous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. JNCI 82:1046–1050 (1990).CrossRefPubMedGoogle Scholar
  21. [21]
    Brienza S, Vignoud J, Itzhaki M: Oxaliplatin (L-OHP): Global safety in 682 patients. Proc. of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, (1995) (Abs 140).Google Scholar
  22. [22]
    Brienza S, Fandi A, Hugret F et al: Neurotoxicity (NTX) of long term oxaliplatin (L-OHP). Proc Am As Can Res 34:406 (1994).Google Scholar
  23. [23]
    Llory JF, Soulie P, Cvitkovic E et al: Feasibility of high-dose Platinum delivery with combined carboplatin and Oxaliplatin. J Natl Cancer Inst 86:1098–1099 (1994).CrossRefPubMedGoogle Scholar
  24. [24]
    Garrino C, Cvitkovic E, Soulie P, et al: Preliminary report on the tolerance of Transplatin (L-OHP) Cisplatin association alone (Bi) or in combination with Ifosfamide and Epirubicin (Bic) in Platinum (Pt) pretreated patients. Proc Am Soc Clin One 13:143 (1994).Google Scholar
  25. [25]
    Soulie P, Llory JF, Fereres M et al: Preliminary results of an active oxaliplatin (L-OHP)-CDDP association based salvage program in pretreated germ cell tumors (GCT). Proc Am Soc Clin Onc 13:250 (1994).Google Scholar
  26. [26]
    Moreau S, Machover D, de Gramont A et al: Phase II trial of Oxaliplatin: in patients with colorectal carcinoma previously resistant to 5-FUFOL. Proc Am Soc Clin Onc 12:214 (1993) (Abs 645).Google Scholar
  27. [27]
    Diaz-Rubio E, Marty M, Extra JM: Multicentric phase II study with Oxaliplatin (L-OHP) in 5-FU refractory patients with advanced colorectal cancer. Proc of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, (1995) (Abs 140).Google Scholar
  28. [28]
    Lévi F, Perpoint B, Garufi C et al: Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continous venous infusion at circadian-rhythm modulated rate. Eur J Cancer 29A:1284–1293 (1993).Google Scholar
  29. [29]
    Lévi F, Zidani R, Giachetti S et al: Chronomodulation of combined Platinum complexes and 5-Fluorouracil delivery. Proc of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, (1995) (Abs 135).Google Scholar
  30. [30]
    De Gramont A, Tournigand C, Louvet C et al: High-dose Folinic Acid, 5-fluorouracil 48H-infusion and Oxaliplatin in metastatic colorectal cancer. Proc of the Fifth International Congress on Anti-Cancer Chemotherapy. Paris, (1995) (Abs 0269).Google Scholar
  31. [31]
    Garufi C, Bensmaïne MA, Brienza S et al: Addition of Oxaliplatin to chronomodulated 5-FU and Folinic Acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, (1995) (Abs S 125).Google Scholar
  32. [32]
    Chollet P, Brienza S, Bensmaïne MA: Report of phase II of Oxaliplatin (L-OHP): a new active agent in platinum pretreated ovarian cancer. Proc of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, (1995) (Abs 137).Google Scholar
  33. [33]
    Cvitkovic E, Bensmaïne MA, Soulié P et al: High activity of combined Oxaliplatin (LOHP) Cisplatin as salvage treatment in pretreated ovarian cancer. Proceedings of 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, (1995) (Abs S 125).Google Scholar
  34. [34]
    Levin L, Simon R, Hryniuk W: Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. JNCI 85:1732–1742 (1993).CrossRefPubMedGoogle Scholar
  35. [35]
    Kaye SB, Lewis CR, Paul J et al: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329–33 (1992).CrossRefPubMedGoogle Scholar
  36. [36]
    Soulié P, Llory JF, Férérès M et al: Prliminary results of an ative oxaliplatin (LOHP)-CDDP association based salvage program in pretreated germ cell tumors (GCT). Proc Am Soc Can Oncol 13:250 (1994).Google Scholar
  37. [37]
    Gastiaburu J, Brienza S, Rotarski M et al: Oxaliplatin (L-OHP): a new platinum analog, active in refractory/relapsed intermediate and low grade LNH. A phase II study. ECCO 7, Jerusalem, (1993) (Abst 980).Google Scholar
  38. [38]
    Monnet I, Brienza S, Voisin S et al: Phase II study of Oxaliplatin (L-OHP) in patients with advanced non small cell lung cancer (NSCLC): preliminary results. Eur J Cancer 29A: S763 (1993) (Abst 901).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • P. Soulié
    • 1
  • E. Raymond
    • 1
  • J. L. Misset
    • 1
  • E. Cvitkovic
    • 1
  1. 1.Service des Maladies Sanguines et TumoralesHôpital Paul BrousseVillejuifFrance

Personalised recommendations